Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons

World Health Organization (2006) Annex 7: multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. In: WHO technical report series 937: WHO expert committee on specifications for pharmaceutical preparations. WHO Press, Geneva, pp. 347–390

US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2003) Bioavailability and bioequivalence. Studies for orally administered drug products-general considerations. CDER, Washington D.C.

Committee for Medicinal Products for Human Use (CHMP) (2010) Guideline on the investigation of bioequivalence. European Medicines Agency (EMA), London

Chow, S.C., Liu, J.P., (2000) Design and analysis of bioavailability and bioequivalence studies. 2nd ed. New York: Marcel Dekker.

Gwaza L, Gordon J, Welink J, Potthast H, Hansson H, Stahl M, et al (2012) (2012) Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120 mg tablets as prequalified by WHO. Eur J Clin Pharmacol 68:1611–1618

‘t Hoen EF, Hogerzeil HV, Quick JD, Sillo HB (2014) A quiet revolution in global public health: the World Health Organization's prequalification of medicines programme. J Public Health Policy 35(2):137–161

Song F, Harvey I, Lilford R (2008) Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 61(5):455–463

Karalis V, Bialer M, Macheras P (2013) Quantitative assessment of the switchability of generic products. Eur J Pharm Sci 50(3–4):476–483

Gwaza L, Gordon J, Potthast H, Welink J, Leufkens H, Stahl M, et al (2014) Adjusted indirect treatment comparison of the bioavailability of WHO-prequalified first-line generic antituberculosis medicines. Clin Pharmacol Ther 96(5):580–588

Karalis V, Macheras P, Bialer M (2014) Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations. CNS Drugs 28(1):69–77

Julious SA (2004) Sample sizes for clinical trials with normal data. Stat Med 23(12):1921–1986

The European Parliament and the Council of the European Union (2001) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use. Off J Eur Communities 311:108

The United States Pharmacopeia Convention. Carbamazepine tablets USP (2009).

Boix-Montañes A, Garcia-Arieta A. (2015) Composition specification of teicoplanin based on its estimated relative bioavailability. Drug Dev Ind Pharm 41(2):218–23

Anderson S, Hauck WW (1996) The transitivity of bioequivalence testing: potential for drift. Int J Clin Pharmacol Ther 34(9):369–374

Herranz M, Morales-Alcelay S, Corredera-Hernandez MT, de la Torre-Alvarado JM, Blazquez-Perez A, Suarez-Gea ML, et al (2013) Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison. Eur J Clin Pharmacol 69:1157–1162